Work

Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease

Year: 2022

Type: editorial

Abstract: LINKED CONTENT This article is linked to Xie et al papers. To view these articles, visit https://doi.org/10.1111/apt.16727 and https://doi.org/10.1111/apt.16773

Source: Alimentary Pharmacology & Therapeutics

DOI: 10.1111/apt.16755

Authors: Robert M. Wilechansky, Tracey G. Simon

Institutions: Harvard University, Massachusetts General Hospital

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Dana-Farber/Harvard Cancer Center, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Award: Aspirin and Novel Lipid Mediators in Nonalcoholic Fatty Liver Disease

OpenAlex ID: W4210538061

Cites: 8

Cited by: 1

Related to: 10